DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

2032
INDEX
Gynecology, drug therapy in,
1837–1845
Gyromitra, 225
H
Haemophilus influenzae, ABC
transporter in, 100f
Hageman factor, 929
Hailey-Hailey disease, dapsone for,
1823
Hair, drug absorption into, 1804
Halazepam
administration and uses of, 466t
structure of, 459t
Halbetasol propionate, 1808t
Halcinonide
cream, 1225t
ointment, 1225t
HALCION (triazolam), 466t
Half-life
alteration for individual patients,
1807–1808
of common drugs, 1809t–1890t
definition of, 32–33
as pharmacodynamic parameter,
1804
Halobetasol propionate ointment,
1225t
HALOG-E (halcinonide cream), 1225t
HALOG (halcinonide), 1225t
Haloperidol
arrhythmias caused by, 832
dosage of, 424t, 425t
metabolism of, 434t
pharmacokinetics of, 1847t
polymorphisms and response to,
160t
potencies at neurotransmitter
receptors, 427t
side effects of, 424t
and vasopressin secretion, 704
Haloprogin, 1588
Halothane, 546–547
Haplotype, 148–149
Haploview, 149, 149f
Hapten, 76
Hardy-Weinberg equilibrium, 152
hCG. See Human chorionic
gonadotropin (hCG)
Headache, vascular, angina pectoris
with, recommended
treatment for, 769t
Head and neck cancer, 1736–1737
drugs for, 1668t–1670t
HEALON (hyaluronate), 1790
Healthcare, funding of, 11–12
Heart
alpha adrenergic receptors in, 203t
anticholinesterase agents and,
246–247
in autonomic nervous system, 178t
beta adrenergic receptors in, 204t
with diastolic dysfunction, pressurevolume
relationships in, 806f
dopamine and, 355
eicosanoids and, 948
epinephrine and, 284–285
histamine effects on, 917
muscarinic antagonists and,
227–228
normal, pressure-volume
relationships in, 806f
Heart disease, ischemic, 751–788
pathophysiology of, 751–753
Heart failure. See also Congestive
heart failure
alpha-adrenergic agonists for, 308
beta-adrenergic agonists for,
804–805
beta-adrenergic receptor antagonists
for, 317–318, 800–801
cardiac glycosides for, 801–804
chronic positive inotropic therapy
for, 805
definition of, 790
diastolic, 805–806, 806f
direct renin inhibitors for, 799
diuretics for, 699–701, 790–793
dopamineregic agonists for,
804–805
hemodynamic responses to
pharmacological
interventions in, 792f
loop diuretics for, 790–791
nitrates for, 760
pathophysiology of, 791f
phosphodiesterase inhibitors for, 805
sites of drug action in, 791f
stages of, 808, 809f
sympathomimetic drugs for, 302
thiazide diuretics for, 791
vasodilators for, 793–797
vasopressin receptor antagonists for,
799–800
Heart Outcomes Prevention Evaluation
(HOPE) study, 735
Heart rate
acetylcholine and, 220–221
muscarinic antagonists and,
227–228
Heavy metals
bone binding and, 24–25
dose-response curve for, 74f
as environmental toxins, 1860–1872
treatment of exposure to, 1872–1876
Helicobacter pylori infection, 1320
Helium, 564–559
Helminthiasis, 1444–1449
chemotherapy for, 1449–1459
Hematopoietic agents, growth factors,
1067–1076
erythropoiesis stimulating agents,
1068–1073
history of, 1067–1068
myeloid, 1070t, 1073–1076
physiology of, 1068, 1070t
thrombopoietic, 1075–1076
Heme
biosynthesis, pathway, 1815f
in drug metabolism, 127
Hemicholinium, 206t
Hemochromatosis, 102t, 103t
Hemolytic anemia
SLC transporters and, 102t
sulfonamides and, 1467
Hemorrhage, postpartum, 1850–1851
Hemorrhagic disease of the newborn,
873–874
Henderson-Hasselbach equation, 19
Heparin, 849. See also Low molecular
weight heparin (LMWH)
adverse effects and side effects of,
858–859
and antianginal therapy, 752
clinical use and monitoring of, 865
derivatives, 854
features of, 854t
hypoglycemia and, 1248t
mechanism of action of, 856f
pharmacokinetics of, 1847t
pharmacological effects of, 854–855
structure of, 855, 855f
therapeutic uses of, 855–857
in myocardial ischemia, 771
thrombocytopenia caused by, 859,
864–865
USP unit dose, 854
Hepatic clearance, 29–30
Hepatic drug transporters, 90f
Hepatic glucose metabolism, in
diabetes, 1247
Hepatic lipase (HL), 881, 884
Hepatic transporters, 108–111
Hepatic uptake, transporters in,
110–111